Transgenesis 2029: Fides #[nn]
☆ Be the first to review + Add to your collection — Join freeThis volume collects the opening chapters of the Transgenesis 2029: Fides storyline, a DC-published series set in a near-future where genetic engineering and corporate power collide. The story follows characters navigating a world transformed by transhumanism, with the narrative centered on themes of identity and control as the year 2029 approaches.
In "Opus Matrice," writer Anne Ploy and artist Didier Pagot launch a gripping tale set in a France ruled by a theocratic regime that uses a bio-engineered virus to eliminate dissent. Marie, a counter-revolutionist, makes a desperate move before capture, slipping vital medical supplies into the pocket of a stranger named Janos—only for him to discover the delivery address leads to his own father’s bookstore. The cover by Didier Pagot captures the tension of this pivotal moment.
In the rigidly controlled France of 2029, where faith is enforced by a bio-engineered virus, Marie Appton risks everything to smuggle life-saving medicine. On a train under surveillance, she slips the supplies into Janos Zinief’s pocket with a desperate plea—deliver them to the address on the package. When Janos later learns the address leads to his father’s bookstore, he’s thrust into a secret world of resistance, forced to confront the truth behind the regime and the past he never knew.
In "Fines Matrices," Josh Zinief is thrust into a dangerous mission when he’s implanted with a virus and sent to infiltrate the counter-revolutionists, forced to play a double game. With an escape meticulously staged, he’s set to return to the base with Marie Appton—though the true cost of their reunion remains uncertain.
ComicBooks.com Value
Find on ebay
Where to buy
Sell my copy
Have this issue — or a whole collection? Get a fair offer from us, skip the marketplace fees and the hassle.
We Buy Collections ▸Full credits
Reprints
↩ Reprints Transgénèse Fides #1 (1999), Transgénèse Fides #2
Reviews
Reader reviews
No reader reviews yet.